Logo image
Surface engineering tumor cells with adjuvant-loaded particles for use as cancer vaccines
Journal article   Peer reviewed

Surface engineering tumor cells with adjuvant-loaded particles for use as cancer vaccines

Kawther K Ahmed, Sean M Geary and Aliasger K Salem
Journal of controlled release, Vol.248, pp.1-9
02/28/2017
DOI: 10.1016/j.jconrel.2016.12.036
PMCID: PMC5309920
PMID: 28057523
url
http://doi.org/10.1016/j.jconrel.2016.12.036View
Open Access

Abstract

Cell surface engineering is an expanding field and whilst extensive research has been performed decorating cell surfaces with biomolecules, the engineering of cell surfaces with particles has been a largely unexploited area. This study reports on the assembly of cell-particle hybrids where irradiated tumor cells were surface engineered with adjuvant-loaded, biodegradable, biocompatible, polymeric particles, with the aim of generating a construct capable of functioning as a therapeutic cancer vaccine. Successfully assembled cell-particle hybrids presented here comprised either melanoma cells or prostate cancer cells stably adorned with Toll-like receptor-9 ligand-loaded particles using streptavidin–biotin cross-linking. Both cell-particle assemblies were tested in vivo for their potential as therapeutic cancer vaccines yielding promising therapeutic results for the prostate cancer model. The ramifications of results obtained for both tumor models are openly discussed. [Display omitted]
Cancer vaccines PLGA particles Streptavidin-biotin cross-linking Cell surface engineering

Details

Metrics

Logo image